Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints

Executive Summary

Merck's Keytruda gains huge advantage in first-line lung cancer as Bristol's stumble in patients with lower expression of PD-L-1 biomarker raises questions about cut-off levels in trials.

Advertisement

Related Content

Tumor Mutation Burden Biomarker Emerges In Bristol's '026 Lung Cancer Post Mortem
Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer
Medivation Sees Potential For Combinations Out Of Opdivo Failure
Opdivo Fallout: Rivalry In PD-1 Market To Continue, More Trials Could Mean More Failures
Does CheckMate 026 Take Bristol Out Of The End Game?
Merck Defends Its Offensive Strategy For Keytruda
Bristol's Oncology Strategy: Cover All The Bases To Keep The Lead
Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer
Merck Is Finding PD-L1 Testing Is Helping Keytruda

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118916

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel